| Cat. No. |
Product Name |
CAS No. |
Information |
| H8950 |
Itacnosertib
|
1628870-27-8 |
Itacnosertib is a potent,an orally ALK2 or ACVR1 protein inhibitor,with IC50 value of 5 nM. |
| H6372 |
GBT-440
|
1446321-46-5 |
A new potent allosteric effector of sickle cell hemoglobin; increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions; orally bioavailable and partitions highly and favorably into the red blood cell with a RBC/plasma ratio of ∼150.
|
| H5818 |
Vadadustat
|
1000025-07-9 |
Vadadustat (PG-1016548, AKB-6548)?is a novel, potent, orally active HIF-PH inhibitor in development for the treatment of anemia in both nondialysis-dependent (NDD) and dialysis-dependent CKD; induces endogenous erythropoietin synthesis and enhances iron mobilization. |
| H5814 |
Roxadustat
|
808118-40-3 |
Roxadustat (FG4592, FG-4592) is a potent, orally available HIF prolyl hydroxylase (HIF-PHD) with IC50 of 591.4 nM; FG-4592 stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, demonstrates potential for treatment of anemia. |
| H5807 |
Molidustat
|
1154028-82-6 |
Molidustat (BAY 85-3934) is an orally active small molecule inhibitor of hypoxia inducible factor prolyl hydroxylase (HIF-PH) with IC50 of 480 nM, 280 nM and 450 nM for PHD1, PHD2, and PHD3, respectively; causes dose-dependent production of erythropoietin (EPO) in healthy Wistar rats and cynomolgus monkeys, increases hemoglobin levels and shows effectivity in the treatment of renal anemia in rats with impaired kidney function, resultsin normalization of hypertensive blood pressure in rat model of CKD. |
| H5801 |
JTZ-951 hydrochloride
|
1262131-60-1 |
A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2; increases EPO release from Hep3B cells with EC50 of 5.7 uM, increases hemoglobin levels in rats. |
| H5800 |
JTZ-951
|
1262132-81-9 |
A novel potent, orally active HIF prolyl hydroxylase (PHD) inhibitor with IC50 of 0.22 uM for PHD2; increases EPO release from Hep3B cells with EC50 of 5.7 uM, increases hemoglobin levels in rats. |
| H5790 |
Desidustat
|
1616690-16-4 |
A novel HIF prolyl hydroxylase (PHD) inhibitor under clinical development for the treatment of anemia; increases circulating EPO levels after acute treatment in mice (10.3±3.7 and 40.0±8.5 fold rise at 15 and 30 mg/kg, respectively); demonstrates hematinic potential by combined effects on EPO release and efficient iron utilization in nephrectomized rats. |
| H5789 |
Daprodustat
|
960539-70-2 |
A nove, orally active HIF-prolyl hydroxylase (PHD) inhibitor that stimulate endogenous EPO synthesis and induces effective erythropoiesis by non-EPO effects; shows potential for the treatment of anemia associated with chronic kidney disease. |
| H4676 |
NS-3623
|
343630-41-1 |
A novel human RBC Cl-conductance blocker (IC50=210 nM) and HERG channel activitor (EC50=79.4 uM, HERG1 channel activation); inhibits RBC g(Cl) after oral administration to normal mice (ED50= 25 mg/kg), ameliorates erythrocyte dehydration in transgenic SAD mice; increases the macroscopic current conducted by the hERG channels by increasing the time constant for channel inactivation; affects native I(Kr), decreases QT variability and distinctly decreases the occurrence of extrasystoles in the acutely bradypaced hearts. |
$ USD
Select Your Country or Region